Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven ...

RXRX remains down by 35% year-to-date and is trading below $5. Thus, the critical question isn’t about a single good ...

Recursion Pharmaceuticals, Inc. is rated a Sell due to cash burn, Q3 net loss of $162.25M and operational trends. Learn more ...

'Mad Money' host Jim Cramer weighs in on stocks including: Recursion Pharmaceuticals and NuScale Power. Lawmakers split after viewing boat strike video: Democrat calls it 'one of the most troubling ...

REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Three recent graduates from the MSU photo program noticed a glaring gap in the photo-journal world. While there has been ...

Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

The simulation hypothesis — the idea that our universe might be an artificial construct running on some advanced alien ...

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

Recursion Pharmaceuticals (RXRX) is drawing renewed attention after the appointment of Najat Khan as CEO and news of a narrowing net loss, both viewed as signals of improving execution. Investors also ...

And other pharma news rounded up from around the Pharmalot campus, as told to you by the Pharmalittle newsletter ...